CORPORACIO SANITARIA PARC TAULI DE SABADELL

Their core work

Parc Taulí is a public hospital and research centre in Sabadell (near Barcelona) with clinical research capabilities in intensive care medicine and patient monitoring. They contribute clinical expertise and patient access to EU research projects focused on bedside diagnostic technologies, telemedicine for critically ill patients, and nanosensor-based diagnostics. Their work bridges the gap between medical device development and real-world clinical validation in hospital settings, particularly in ICU environments.

What they specialise in

How they've shifted over time

Their early H2020 work (2015-2016) touched nanomedicine and nanosensor diagnostics for genetic diseases like cystic fibrosis, alongside hospital telemedicine systems. By 2020, their focus shifted decisively toward bedside optical monitoring in intensive care — biophotonics, tissue oxygenation measurement, and microvascular health assessment, likely accelerated by COVID-19 ICU demands. The trajectory shows a narrowing from broad health technology participation toward specialized ICU diagnostic monitoring.

CSPT is moving toward portable, bedside optical diagnostics for critically ill patients — a growing field where clinical validation partners with ICU access are in high demand.

How they like to work

CSPT participates exclusively as a partner, never as coordinator, which is consistent with a hospital providing clinical sites and patient data rather than leading technology development. With 15 unique partners across 6 countries in just 3 projects, they join moderately sized consortia and do not appear to repeat partnerships, suggesting they are recruited for their clinical infrastructure rather than existing network ties. They are a reliable clinical endpoint in technology-driven consortia.

Across 3 projects, CSPT has collaborated with 15 distinct partners in 6 countries, indicating they join diverse European consortia rather than operating within a fixed network. Their partnerships span technology developers and other clinical centres.

What sets them apart

As a major public hospital near Barcelona with active research infrastructure, CSPT offers something technology developers need but often struggle to find: direct access to ICU patients and clinical validation environments. Their progression from nanomedicine to biophotonics-based ICU monitoring shows they can adapt to emerging medical technology trends. For any consortium developing bedside diagnostic devices or critical care monitoring tools, CSPT provides the clinical trial site and medical expertise to move from lab prototype to validated medical product.

Highlights from their portfolio

• VASCOVID
  Their largest funded project (EUR 222,302), developing a portable platform for microvascular assessment in COVID-19 ICU patients using near-infrared spectroscopy — directly relevant to pandemic-era critical care.
• THALEA II
  A Pre-Commercial Procurement (PPI) project for hospital telemedicine, an unusual funding scheme that signals CSPT's role as an end-user shaping procurement of health IT solutions.